Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus target price of $3.00 for the company and are forecasting that the company will post ($0.12) EPS for the current quarter, according to Zacks. Zacks has also assigned Bellerophon Therapeutics an industry rank of 112 out of 255 based on the ratings given to its competitors.

BLPH has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Bellerophon Therapeutics in a research note on Thursday, August 2nd. Zacks Investment Research cut shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 11th. Finally, ValuEngine raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 8th.

Shares of BLPH opened at $1.07 on Wednesday. The firm has a market capitalization of $68.20 million, a price-to-earnings ratio of -1.19 and a beta of -0.80. Bellerophon Therapeutics has a 1 year low of $0.47 and a 1 year high of $3.30.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.10). equities research analysts anticipate that Bellerophon Therapeutics will post -0.4 earnings per share for the current fiscal year.

In related news, major shareholder Associates Iv L. P. Venrock bought 160,000 shares of the firm’s stock in a transaction on Friday, September 7th. The shares were bought at an average cost of $0.86 per share, for a total transaction of $137,600.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Associates Iv L. P. Venrock bought 529,370 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were bought at an average price of $0.65 per share, for a total transaction of $344,090.50. The disclosure for this purchase can be found here. Insiders acquired a total of 1,699,370 shares of company stock worth $1,672,941 over the last three months. 57.80% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Bellerophon Therapeutics stock. Renaissance Technologies LLC grew its stake in shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) by 12.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,159,200 shares of the biotechnology company’s stock after purchasing an additional 126,300 shares during the period. Renaissance Technologies LLC owned approximately 2.01% of Bellerophon Therapeutics worth $2,805,000 at the end of the most recent reporting period. Institutional investors own 58.49% of the company’s stock.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Featured Article: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.